Case Study: VaxArt improves norovirus vaccine safety monitoring with ObvioHealth

VaxArt detects severe reactogenicity in the first week with ObvioHealth, while reported crying/fussing ran 2-3x higher than audio-recorded events

VaxArt needed to evaluate the safety and immunogenicity of its orally administered norovirus vaccine, with a specific focus on quickly detecting severe reactogenicity symptoms shortly after administration. To meet this challenge, they partnered with ObvioHealth.

ObvioHealth implemented a virtual clinical trial solution using its proprietary mobile app and platform. This decentralized approach allowed for the rapid detection of symptoms and the collection of necessary data from subjects participating from home. The results successfully supported VaxArt's vaccine development program.

VaxArt